Passage BIO基本情况
情况介绍
Passage Bio (PASG) is a clinical-stage genetic medicines company focused on developing treatments for central nervous system disorders. Founded in 2017 and headquartered in Philadelphia, Pennsylvania, the company went public in 2020. As of the latest data, Passage Bio has a market capitalization of approximately $150 million.
股本股东分析
Passage Bio's total outstanding shares are around 45 million. The major institutional shareholders include OrbiMed Advisors LLC, holding about 10% of the shares, and RA Capital Management, L.P., with approximately 8%. Insider ownership is relatively low at around 2%, indicating a strong institutional backing.
经营能力分析
In 2022, Passage Bio reported a net loss of $130 million, with R&D expenses amounting to $100 million. The company's cash reserves stood at $200 million at the end of the year, providing a runway of approximately 18 months. The operating margin was negative, reflecting the company's focus on research and development rather than revenue generation.
竞争能力分析
Passage Bio operates in a highly competitive field of gene therapy, with major competitors including Biogen, Novartis, and Bluebird Bio. The company's competitive edge lies in its proprietary platform, which has shown promising results in early-stage clinical trials. However, the company's smaller size and limited product pipeline compared to its competitors pose challenges.
发展情景分析
Passage Bio is currently advancing multiple clinical programs, with its lead candidate, PBGM01, targeting GM1 gangliosidosis, in Phase 1/2 trials. The company plans to initiate additional clinical trials in 2023 and expects to report interim data by mid-2024. Successful trial outcomes could significantly boost the company's valuation and attract more investment.
重大事项
In early 2023, Passage Bio announced a collaboration with a leading academic institution to accelerate the development of its gene therapy platform. Additionally, the company secured a $50 million equity financing round to support its clinical trials and operational needs.
公司基本情况小结
Passage Bio's investment value hinges on the success of its clinical trials and the potential of its gene therapy platform. The company's strong institutional backing and strategic collaborations are positive indicators, but its high cash burn rate and competitive landscape present risks. Investors should closely monitor clinical trial outcomes and the company's ability to extend its cash runway.
暂无评论内容